Cargando…

Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports

BACKGROUND: In metastatic colorectal cancer (mCRC), the anti-vascular endothelial growth factor drug bevacizumab (BVZ) plus chemotherapy significantly improves progression-free survival compared to chemotherapy (CT) alone. This benefit is not, however, observed in all patients. While increased chemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Novillo, Apolonia, Gaibar, María, Romero-Lorca, Alicia, Gilsanz, María Fuencisla, Beltrán, Laura, Galán, Miguel, Antón, Beatriz, Malón, Diego, Moreno, Amalia, Fernández-Santander, Ana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201148/ https://www.ncbi.nlm.nih.gov/pubmed/32390708 http://dx.doi.org/10.3748/wjg.v26.i16.1979

Ejemplares similares

miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer
por: Romero-Lorca, Alicia, et al.
Publicado: (2021)

Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer
por: Gaibar, María, et al.
Publicado: (2021)

FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
por: Gaibar, María, et al.
Publicado: (2022)

HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment
por: Novillo, Apolonia, et al.
Publicado: (2023)

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer
por: Gaibar, Maria, et al.
Publicado: (2020)

Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
por: Romero-Lorca, Alicia, et al.
Publicado: (2015)

Differential expression of PMCA2 mRNA isoforms in a cohort of Spanish patients with breast tumor types
por: Romero-Lorca, Alicia, et al.
Publicado: (2018)

Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer
por: Novillo, Apolonia, et al.
Publicado: (2021)

Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients
por: Fernández-Santander, Ana, et al.
Publicado: (2013)

Pharmacogenetics of ugt genes in North African populations
por: Gaibar, M., et al.
Publicado: (2018)

Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
por: Chen, Clara, et al.
Publicado: (2015)

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment
por: Hosoda, Shunichi, et al.
Publicado: (2022)

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy
por: Österlund, P, et al.
Publicado: (2011)

Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer
por: Wu, Qian, et al.
Publicado: (2013)

The chemokine CXCL16 modulates neurotransmitter release in hippocampal CA1 area
por: Di Castro, Maria Amalia, et al.
Publicado: (2016)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013)

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer
por: LIM, SUNG HEE, et al.
Publicado: (2023)

CXCL14-Like Immunoreactivity Exists in Somatostatin-Containing Cells of Mouse Pancreas
por: Suzuki, Hirohumi, et al.
Publicado: (2015)

CXCL5 and CXCL14, but not CXCL16 as potential biomarkers of colorectal cancer
por: Zajkowska, Monika, et al.
Publicado: (2023)

Overproduction of CXC chemokines CXCL1, CXCL9, CXCL10 and CXCL12 in β-thalassemia major or patients
por: Najmaddini, Hamid, et al.
Publicado: (2014)

CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic hepatitis B
por: Yu, Xin, et al.
Publicado: (2022)

High Levels of CXCL8 and Low Levels of CXCL9 and CXCL10 in Women with Maternal RhD Alloimmunization
por: Schettini, Juliana Araújo de Carvalho, et al.
Publicado: (2017)

CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients
por: Wang, Cuini, et al.
Publicado: (2016)

CXCL10 Controls Inflammatory Pain via Opioid Peptide-Containing Macrophages in Electroacupuncture
por: Wang, Ying, et al.
Publicado: (2014)

CXCL8, CXCL9, and CXCL10 serum levels increase in syphilitic patients with seroresistance
por: Dong, Xiaoyan, et al.
Publicado: (2021)

Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
por: Abajo, A, et al.
Publicado: (2012)

Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer
por: Hagman, Helga, et al.
Publicado: (2018)

Posterior Reversible Encephalopathy Syndrome after a Variety of Combined Chemotherapies Containing Bevacizumab for Metastatic Colon Cancer
por: Katada, Eiichi, et al.
Publicado: (2018)

Treatment outcomes of injectable thermosensitive hydrogel containing bevacizumab in intervertebral disc degeneration
por: Chen, Qian, et al.
Publicado: (2022)

First line targeted therapies in breast cancer: focus on bevacizumab
por: Milano, Amalia, et al.
Publicado: (2007)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo, Maria, et al.
Publicado: (2015)

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
por: Rosen, Virginia M., et al.
Publicado: (2017)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

The Effect of Transplantation of Cultured Autologous Melanocytes on CXCL9, CXCL10 and CXCL11 Expressions in Vitiligo
por: Xu, Chen, et al.
Publicado: (2023)

Seminal Levels of Pro-inflammatory (CXCL1, CXCL9, CXCL10) and Homeostatic (CXCL12) Chemokines in Men With Asymptomatic Chlamydia trachomatis Infection
por: Hakimi, Hamid, et al.
Publicado: (2014)

Correction: CXCL10 Controls Inflammatory Pain via Opioid Peptide-Containing Macrophages in Electroacupuncture
Publicado: (2014)

COVID-19 Vaccines during Pregnancy and Breastfeeding: A Systematic Review
por: Novillo, Blanca, et al.
Publicado: (2022)

Association of circulating CXCL10 and CXCL11 with systemic sclerosis
por: Crescioli, Clara, et al.
Publicado: (2018)

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
por: Kim, Seung Tae, et al.
Publicado: (2018)

Human brain metastatic stroma attracts breast cancer cells via chemokines CXCL16 and CXCL12
por: Chung, Brile, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6g4lkkvbh4in0qnpr3d648jpbs